-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Felodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group
Category:
TIME：2025-04-10
Recently, the felodipine API developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has received national approval and been registered as an API for use in marketed dosage forms.
To date, the Group has received approval for a total of 72 active pharmaceutical ingredient (API) products. As a key R&D and industrialization hub for the Group’s integrated API–formulation development strategy, Guangxiang Pharmaceutical currently boasts 41 bulk and specialty APIs.
According to available information, felodipine is primarily used for the treatment of mild to moderate primary hypertension and stable angina pectoris.
Previously, Shijiazhuang Sihua Pharmaceutical’s 5 mg felodipine sustained-release tablets were approved by the National Medical Products Administration in January 2023, which was deemed equivalent to passing the evaluation of quality and therapeutic equivalence for generic drugs, and the product was subsequently selected in the eighth round of national centralized drug procurement in April of the same year. The approval of the felodipine API this time will further strengthen the Group’s integrated, synergistic capabilities in both API and formulation development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
